Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse

Experimental Neurology

Volumn 237, Issue 2, 2012, Pages 304-311

  Sun, Xiaojia ^a   Liu, Yuting ^b   Liu, Boyang ^a   Xiao, Zhicheng ^c,d   Zhang, Liming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c MONASH UNIVERSITY   (Australia)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Cuprizone; Demyelination; MAPK; Oligodendrocyte precursor cell; PDE4 inhibitor; Remyelination; Rolipram

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; CUPRIZONE; FAST BLUE; LYSOPHOSPHATIDYLCHOLINE; MITOGEN ACTIVATED PROTEIN KINASE; MYELIN BASIC PROTEIN; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MATURATION; CEREBELLUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVITY; IN VITRO STUDY; MALE; MOUSE; NEURAL STEM CELL; NEWBORN; NONHUMAN; OLIGODENDROCYTE PERCURSOR CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REMYELINIZATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; CELL DIFFERENTIATION; CUPRIZONE; DEMYELINATING DISEASES; LYSOPHOSPHATIDYLCHOLINES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE INHIBITORS; OLIGODENDROGLIA; ORGAN CULTURE TECHNIQUES; PHOSPHODIESTERASE 4 INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; STEM CELLS;

EID: 84864798615     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.07.011     Document Type: Article

References (39)

1. Afshari F.S., Chu A.K., Sato-Bigbee C. Effect of cyclic AMP on the expression of myelin basic protein species and myelin proteolipid protein in committed oligodendrocytes: differential involvement of the transcription factor CREB. J. Neurosci. Res. 2001, 66:37-45.
2. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F. Treatment of relapsing paralysis in experimental encephalitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725-733.
3. Aktas O., Keiseier B., Hartung H.-P. Neuroprotection, regeneration and immunomodulation: broadening the repertoire in multiple sclerosis. Trends Neurosci. 2009, 33:140-150.
4. Baas D., Legrand C., Samarut J., Flamant F. Persistence of oligodendrocyte precursor cells and altered myelination in optic nerve associated to retinal degeneration in mice devoid of all thyroid hormone receptors. PNAS 2002, 99:2907-2911.
5. Bielekova B., Lincoln A., McFarland H., Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 2000, 164:1117-1124.
6. Bielekova B., Richert N., Howard T., Packer A.N., Blevins G., Ohayon J., McFarland H.F., Sturzebecher C.-S., Martin R. Treatment with the phosphodiesterase type 4 inhibitor rolipram fails to inhibit blood brain barrier disruption in multiple sclerosis. Mult. Scler. 2009, 15(10):1206-1214.
7. Birgbauer E., Rao T.S., Webb M. Lysolecithin induces demyelination in vitro in a cerebellar slice culture system. J. Neurosci. Res. 2004, 78:157-166.
8. Chang A., Tourtellotte W.W., Rudick R., Trapp B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 2002, 346:165-173.
9. Chen Y., Balasubramaniyan V., Peng J., Hurlock E.C., Tallquist M., Li J., Lu Q.R. Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat. Protoc. 2007, 2:1044-1051.
10. Domeniconi M., Filbin M.T. Overcoming inhibitors in myelin to promote axonal regeneration. J. Neurol. Sci. 2005, 233:43-47.
11. Dutta R., Trapp B.D. Mechanisms of neuronal dysfunction and degenreation in multile sclerosis. Prog. Neurol. 2011, 93:1-12.
12. Folcik V.A., Smith T., O'Bryant S., Kawczak J.A., Zhu B., Sakurai H., Kajiwara A., Staddon J.M., Glabinski A., Chernosky A.L., Tani M., Johnson J.M., Tuohy V.K., Rubin L.L., Ransohoff R.M. Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol. 1999, 97:119-128.
13. Fyffe-Maricich S.L., Karlo J.C., Landreth G.E., Miller R.H. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J. Neurosci. 2011, 31:843-850.
14. Galabova-Kovacs G., Catalanotti F., Matzen D., Reyes G.X., Zezula J., Herbst R., Silva A., Walter I., Baccarini M. Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. J. Cell Biol. 2008, 180:947-955.
15. Genain C.P., Roberts T., Davis R.L., Nguyen M.H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3601-3605.
16. Jung S., Zielasek J., Kollner G., Donhauser T., Toyka K., Hartung H.P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 1996, 68:1-11.
17. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol. 2009, 118:723-736.
18. Kuhlmann T., Miron V., Cui Q., Wegner C., Antel J., Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008, 131:1749-1758.
19. Lee J., Gravel M., Gao E., O'Neill R.C., Braun P.E. Identification of essential residues in 2',3'-cyclic nucleotide 3'-phosphodiesterase. Chemical modification and site-directed mutagenesis to investigate the role of cysteine and histidine residues in enzymatic activity. J. Biol. Chem. 2001, 276:14804-14813.
20. Lindner M., Heine S., Haastert K., Garde N., Fokuhl J., Linsmeier F., Grothe C., Baumgartner W., Stangel M. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol. Appl. Neurobiol. 2008, 34:105-114.
21. Martinez I., Puerta C., Redondo C., Garcia-Merino A. Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase. J. Neurol. Sci. 1999, 164:13-23.
22. Newbern J.M., Li X., Shoemaker S.E., Chou J., Zhong J., Wu Y., Bonder D., Hollenbeck S., Coppola G., Geschwind D.H., Landreth G.E., Snider W.D. Specific functions for ERK/MAPK signaling during PNS development. Neuron 2011, 15:91-105.
23. Paintlia A.S., Paintlia M.K., Singh I., Singh A.K. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp. Neurol. 2008, 214:168-180.
24. Paintlia A.S., Paintlia M.K., Singh I., Skoff R.B., Singh A.K. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 2009, 57:182-193.
25. Ravni A., Vaudry D., Gerdin M.J., Eiden M.V., Falluel-Morel A., Gonzalez B.J., Vaudry H., Eiden L.E. A cAMP-dependent, protein kinase A-independent signaling pathway mediating neuritogenesis through Egr1 in PC12 cells. Mol. Pharmacol. 2008, 73:1688-1708.
26. Sanchez A.J., Puerta C., Ballester S., Gonzalez P., Arriaga A., Garcia-Merino A. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 168:13-20.
27. Smith K.J., Bostock H., Hall S.M. Saltatory conduction precedes remyelination in axons demyelinated with lysophosphatidyl choline. J. Neurol. Sci. 1982, 54:13-31.
28. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1995, 1:244-248.
29. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Loschmann P.A., Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 1997, 79:54-61.
30. Song H.J., Ming G.L., Poo M.M. cAMP-induced switching in turning direction of nerve growth cones. Nature 1997, 388:275-279.
31. Stachowiak E.K., Fang X., Myers J., Dunham S., Stachowiak M.K. cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). J. Neurochem. 2003, 84:1296-1312.
32. Stoppini L., Buchs P.A., Muller D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 1991, 37:173-182.
33. Studzinski D.M., Ramaswamy R., Benjamins J.A. Effects of cyclic AMP on expression of myelin genes in the N20.1 oligodendroglial cell line. Neurochem. Res. 1998, 23:435-441.
34. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
35. Whitaker C.M., Beaumont E., Wells M.J., Magnuson D.S., Hetman M., Onifer S.M. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci. Lett. 2008, 438:200-204.
36. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 1998, 18:601-609.
37. Younes-Rapozo V., Felgueiras L.O., Viana N.L., Fierro I.M., Barja-Fidalgo C., Manhaes A.C., Barradas P.C. A role for the MAPK/ERK pathway in oligodendroglial differentiation in vitro: stage specific effects on cell branching. Int. J. Dev. Neurosci. 2009, 27:757-768.
38. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
39. Zhang B., Yang L., Konishi Y., Maeda N., Sakanaka M., Tanaka J. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 2002, 42:262-269.